Abstract:Degradation of unliganded androgen receptor (AR) in prostate cancer cells can be prevented by proteasome inhibition, but this is associated with only modest increases in polyubiquitylated AR. An inhibitor (VLX1570) of the deubiquitylases associated with the proteasome did not increase ubiquitylation of unliganded AR, indicating that AR is not targeted by these deubiquitylases. We then identified a series of AR ubiquitylation sites, including a not previously identified site at K911, as well as methylation sites and previously identified phosphorylation sites. Mutagenesis of K911 increases AR stability, chromatin binding, and transcriptional activity. We further found that K313, a previously reported ubiquitylation site, could also be methylated and acetylated. Mutagenesis of K313, in combination with K318, increases AR transcriptional activity, indicating that distinct posttranslational modifications at K313 differentially regulate AR activity. Together these studies expand the spectrum of AR posttranslational modifications, and indicate that the K911 site may regulate AR turnover on chromatin.

What problem does this paper attempt to address?

This paper aims to solve the problem of the regulation mechanism of the stability and activity of androgen receptor (AR) in prostate cancer cells. Specifically, the research focuses on the following aspects: 1. **AR Degradation Mechanism**: - Unliganded AR is degraded through the ubiquitin - proteasome system (UPS) in prostate cancer cells. However, inhibiting the proteasome can only moderately increase the level of polyubiquitinated AR. - The researchers tested whether inhibiting proteasome - associated deubiquitylases (DUBs) could increase the ubiquitination level of unliganded AR, but found that the inhibitor VLX1570 could not significantly increase the ubiquitination of unliganded AR, indicating that AR may not be the target of these DUBs. 2. **AR Ubiquitination Sites**: - Through mass spectrometry analysis, the researchers identified a series of AR ubiquitination sites, including a previously unreported site K911, as well as known methylation and phosphorylation sites. - Mutating the K911 site can increase the stability, chromatin - binding ability and transcriptional activity of AR. 3. **Multiple Modifications at the K313 Site**: - The K313 site can be not only ubiquitinated, but also methylated and acetylated. Mutating the combination of K313 and K318 sites can increase the transcriptional activity of AR, indicating that different post - translational modifications (PTMs) have different regulatory effects on AR activity at the K313 site. 4. **Function of the K911 Site**: - Mutation of the K911 site not only increases the stability of AR, but also enhances its transcriptional activity. Further research shows that ubiquitination at the K911 site may regulate the turnover of AR on chromatin. In conclusion, this paper expands the understanding of AR post - translational modifications by identifying new AR ubiquitination sites and studying their functions, and reveals the important role of the K911 site in the regulation of AR stability and transcriptional activity. These findings are helpful for in - depth understanding of the mechanism of AR in prostate cancer and provide potential targets for the development of new treatment strategies.

A carboxy-terminal ubiquitylation site regulates androgen receptor activity

UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance

Regulation of Androgen Receptor Transcriptional Activity and Specificity by RNF6-Induced Ubiquitination

Correction: Functional Domain and Motif Analyses of Androgen Receptor Coregulator ARA70 and Its Differential Expression in Prostate Cancer.

Isolation and Characterization of Androgen Receptor Mutant, AR(M749L), with Hypersensitivity to 17-Β Estradiol Treatment

p300-Mediated Acetylation of Histone Demethylase JMJD1A Prevents Its Degradation by Ubiquitin Ligase STUB1 and Enhances Its Activity in Prostate Cancer

Phosphorylation of the androgen receptor at Ser81 is co‐sustained by CDK1 and CDK9 and leads to AR‐mediated transactivation in prostate cancer

Regulating Androgen Receptor Function in Prostate Cancer: Exploring the Diversity of Post-Translational Modifications

Phosphorylation/Dephosphorylation of Androgen Receptor as a Determinant of Androgen Agonistic or Antagonistic Activity

KDM1A triggers androgen-induced miRNA transcription via H3K4me2 demethylation and DNA oxidation

Targeted Degradation of Androgen Receptor by VNPP433-3β in Castration-Resistant Prostate Cancer Cells Implicates Interaction with E3 Ligase MDM2 Resulting in Ubiquitin-Proteasomal Degradation

[Research Progress of the Roles of Ubiquitination/Deubiquitination in Androgen Receptor Abnormalities and Prostate Cancer].

Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer

Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer

PC-1 Works in Conjunction with E3 Ligase CHIP to Regulate Androgen Receptor Stability and Activity

Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC

Genomic Androgen Receptor-Occupied Regions with Different Functions, Defined by Histone Acetylation, Coregulators and Transcriptional Capacity.

Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells

Molecular Dynamics Simulations Revealed the Regulation of Ligands to the Interactions between Androgen Receptor and Its Coactivator

Differential Regulation of Androgen Receptor by Pim-1 Kinases Via Phosphorylation-Dependent Recruitment of Distinct Ubiquitin E3 Ligases

Suppression of Androgen Receptor Transactivation by Pyk2 Via Interaction and Phosphorylation of the ARA55 Coregulator*